Canadian Pharmaceutical Manufacturers Begin to Raise Patented Drug Prices

Research and Markets (researchandmarkets.com/reports/c32147) has announced the addition of Pharmaceutical Pricing and Reimbursement in Canada to their offering.

Dublin (PRWEB) February 8, 2006 -- Research and Markets (http://www.researchandmarkets.com/reports/c32147) has announced the addition of Pharmaceutical Pricing and Reimbursement in Canada to their offering.

Canada is the world’s eighth largest pharmaceutical market, with ex-manufacturer sales of $10 billion in 2004. Canadian ex-manufacturer prices for brand name drugs are close to median European prices but lower than U.S. prices. The growing price gap between Canada and the United States has fueled substantial exports to U.S. consumers, a trade that is technically illegal in the United States and is opposed by the Canadian government. After many years of static prices, manufacturers have begun to raise patented drug prices in Canada, a trend that has disturbed national, provincial, and territorial governments. The highly influential Patented Medicine Prices Review Board (PMPRB) has also criticized price increases and called for stronger cost-containment measures. We begin this report with an overview of the Canadian health care system and pharmaceutical market. We then focus on drug pricing and reimbursement procedures and provide an update on the cross-border trade situation. The Decision Resources report concludes with a brief assessment of the prospects for change in the Canadian pricing and reimbursement environment.

Contents Include:

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

###